Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | -10.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.53 | N/A | -10.42% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about recent performance but remains focused on future growth. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
Tyra Biosciences reported a loss that was slightly worse than expected, contributing to a 0.8% decline in stock price. The lack of revenue details and guidance may raise concerns among investors about the company's near-term prospects. Overall, the report reflects ongoing challenges in the business environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
XPENG INC ADR ADR
Mar 19, 2024